Volume 3, Issue 3, Fall 2024

View Volume 3, Issue 3, Fall 2024

Relapsed or Refractory Mantle Cell Lymphoma: Available and Emerging Therapies
Treatment of Philadelphia Chromosome-negative Myeloproliferative Neoplasms in 2024: A Concise Review
Front-line Treatment of Older Patients with Hodgkin Lymphoma
The Evolving Landscape of DLBCL Treatment Beyond the First Line in 2024
Minimal Residual Disease in Myeloma in 2024: Where We are Today

Published: 2024-12-03

Full Issue

Articles

Relapsed or Refractory Mantle Cell Lymphoma: Available and Emerging Therapies

Jean-Nicolas Champagne, MD, FRCPC, Diego Villa, MD, MPH, FRCPC

5–17
- PDF (en)
- PDF (fr)
Treatment of Philadelphia Chromosome-negative Myeloproliferative Neoplasms in 2024: A Concise Review

Akhil Rajendra, MD, DM, Dawn Maze, MD, FRCPC, MSc

19–31
- PDF (en)
- PDF (fr)
Front-line Treatment of Older Patients with Hodgkin Lymphoma

Kelly Davison, MD

33–37
- PDF (en)
- PDF (fr)
The Evolving Landscape of DLBCL Treatment Beyond the First Line in 2024

Mark Bosch, MD

39–45
- PDF (en)
- PDF (fr)
Minimal Residual Disease in Myeloma in 2024: Where We are Today

Alfredo De la Torre, MD, Ana-Florencia Ramírez Ibarguen, MD

47–54
- PDF (en)
- PDF (fr)